At first I was a little disappointed with the announcement with...

At first I was a little disappointed with the announcement with the delay of the Mobvoi watch by a few weeks but on re reading the announcement carefully this is a very positive update.
I am involved in the development of medical devices so know the hurdles to getting regulatory approval especially FDA clearance and the inevitable delays in product development to ensure the product is both effective (accurate enough to be useful) and safe.
When I review the section reported on regulatory approval below I get very excited.

New Product Regulatory Approval Update: FDA (USA), CE Mark (Europe), NMPA (China)
Details on planned project release dates and regulatory schedules are provided in the specific
project sections above.
No FDA clearance is required for the Company’s first wearable product launch in partnership with
Mobvoi (the MVP).
Arty Band will require FDA clearance as we are seeking to have it classified as a “medical device”
unlike other consumer wearables that are marketed “for wellness purposes” only (such as the Apple
Watch) and thereby avoid having the rigorous scientific testing and validation required for FDA
clearance.
It is important to point out that we see little technology risk or validation hurdles for our FDA
applications as we move forward with this process.
Our existing SphygmoCor® XCEL device is already the “predicate” testing device used by the FDA in
assessing central blood pressure (“cBP”). In effect our new Pulse device will be tested for accuracy
(conducted by the FDA or agents on its behalf) of cBP against our own existing device, additionally,
the brachial blood pressure (“BBP”) validation of Pulse will be based on our OEM manufacturers
(Andon) existing FDA approved BBP device.
I like the strategy for the Arty band, developing it as a high volume medical device that will have credible physiological readings as a wearable lower tier product to Pulse. This is a new product category with no likely competition over the short term. It is all based on the large database AtCor have accumulated from trials and their IP which puts CDX in pole position to succeed and lead this market. The timelines for Arty Band look optimistic but I'm patient and will sit out any delays out as I believe the strategy and knowledge with allow us lead in this massive new market segment.
I starting buying shares in AtCor at 15c and have kept buying in dips and now have a sizable shareholding with average value of 4.5c. I bought more shares today as on balance this is a very positive quarterly update so I see it as a bargain.
I think the product road map for CDX is exceptional, and credible, so I will patiently wait and continue accumulating when I see a bargain in the share price and I am confident I will receive exceptional returns over the next few years. The next 12 months should be spectacular.
I have often read on this CDX forum the comment about poor market updates from management. I hold shares in several microcap technology companies and CDX is the best by miles at providing informative market updates.